Skip to main content
. 2021 Jul 22;43(1):177–193. doi: 10.1038/s41401-021-00715-3

Fig. 2. Cepharanthine enhances the therapeutic efficacy of epirubicin in vivo.

Fig. 2

Sixty-four BALB/c nude mice were inoculated subcutaneously with MDA-MB-231 cells and randomly divided into four groups (16 mice per group, 10 mice were used for determination of survival and 6 mice for determination of tumor volume and H&E, TUNEL, and immunohistochemistry analyses). a Comparison of the overall survival of mice between vehicle, cepharanthine, epirubicin and combination of cepharanthine/epirubicin (n = 10 mice per group). Statistical significance in survival was determined by log-rank test. ***P < 0.01, comparison between epirubicin and cepharanthine/epirubicin. b, c Tumor volumes were measured on the indicated days. Data represented as mean ± SD (n = 6, **P < 0.01, ***P < 0.001, ns not significant, Student’s two-tailed unpaired t-tests). d Body weight of mice was measured on the indicated days. e Representative images of H&E, TUNEL, and immunohistochemistry staining for determination of morphology, apoptosis and expression of C-caspase 3 in xenograft tumor sections. Scar bar, 50 µm.